Safety, tolerability and pharmacokinetics and pharmacodynamics of HL2351, a novel hybrid Fc-fused IL-1 receptor antagonist, in healthy subjects: a first-in-human study.
We performed a first-in-human study with HL2351, a novel hybrid Fc-fused IL-1 receptor antagonist, to evaluate its tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) after a single subcutaneous (SC) administration in healthy subjects. A randomized, double-blind, placebo- and active-controlled, dose-escalation study was conducted. Eligible subjects randomly received a single SC administration of HL2351 (1, 2, 4, 8 and 12 mg/kg) or placebo in a ratio of 8:2. Subjects in the active-controlled group received a single SC administration of anakinra at 100 mg. Serial blood samples were collected for PK and PD analyses. An ex-vivo activation test was performed to evaluate the PD using peripheral blood mononuclear cells treated with IL-1ß. Anti-HL2351 antibodies were determined at baseline and 29 days post-dose. Tolerability was assessed throughout the study. HL2351 was eliminated more slowly than anakinra (terminal half-life: 27.21-45.28 vs. 3.97 hours). Serum concentrations of HL2351 were increased dose-proportionally. The mean apparent clearance of HL2351 were 0.6, 0.66, 0.75, 0.51, 0.65 L/h at 1, 2, 4, 8 and 12 mg/kg, respectively. The percent inhibition of IL-6 expression varied widely (range: 0-92.1%), showing no clear trend or discernible difference between HL2351, anakinra, and placebo. HL2351 was well tolerated after a single SC administration. HL2351 was well tolerated and showed linear pharmacokinetic characteristics after a single SC administration at doses up to 12 mg/kg in healthy subjects. HL2351 remained in the body 7-11 times longer than anakinra. HL2351 can be developed as a potential therapeutic alternative to anakinra.